Newest
-
2025 Friendly Shandong New Year Gala·Dongying Cultural and Tourism Carnival Opened in Dongying
-
Kantar Group announces the proposed sale of Kantar Media
-
Positive phone call offers hope of new beginning for ties that will bear fruit: China Daily editorial
-
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
The film
-
TESSAN and Rachael Yamagata Unveil a Musical Journey: Discover the World Through Song and Story
NEW YORK,Jan. 5,2025-- The leading charging solution brand TESSAN has launched a captivating documentary on YouTube featuring the talented singer-songwriter Rachael Yamagata sharing her creative exper
01-06
Details -
ICZOOM Concluded 2024 with Multiple Awards
HONG KONG,Jan. 3,2025-- ICZOOM Group Inc. (Nasdaq: IZM) (the "Company" or "ICZOOM"),a B2B electronic component products e-commerce platform,announced that it concluded a successful
01-06
Details -
Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
SAN FRANCISCO and SUZHOU,China,Jan. 3,2025-- Innovent Biologics,Inc. ("Innovent") (HKEX: 01801),a world-class biopharmaceutical company that develops,manufactures and commercializes high qua
01-06
Details -
Global Times: China’s role as a stabilizing force crucial for 2025 and beyond
The year 2024 witnessed regional turmoil and profound landscape changes. From the Russia-Ukraine conflict to the chaos in the Middle East and the interference of external forces stirring tensions in the South China Sea, China demonstrated composure and confidence amid a turbulent landscape, creating a favorable external environment for its high-quality development and injecting valuable stability into a restless world. As a member of the Global South, China is playing an increasingly important role in promoting world development and peace, as well as advancing the rise of the Global South. As
01-06
Details -
Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS
NANTONG and SUZHOU,China,Dec. 24,2024-- Ractigen Therapeutics,a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies,today announced the successful dosing of th
01-03
Details -
Treat Yourself to a New Christmas Experience by Self-Gifting viaim's AI Recording Earbuds, Perfect for a More Pleasant and Efficient Workplace
SINGAPORE,Dec. 26,2024-- As Christmas approaches,the concept of self-gifting has become more popular with top business executives to help them get into the holiday mood. Especially designed for the of
01-03
Details -
Xinjiang Kashgar distribution grid achieves "minute-level self-healing" for the first time
KASHGAR,China,Dec. 25,2024--On December 23,the State GridKashgar Power Supply Company successfully implemented the operation of accurate isolation of fault areas and rapid restoration of power supply
01-03
Details -
IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved
SUZHOU,China,Dec. 26,2024-- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033,a high-concentration subcutaneous co-formulation consi
01-03
Details -
My China Story: New Life of "Wanzai Brothers"
YICHUN,China,Dec. 28,2024-- Wanzai,in Jiangxi Province,is the hometown of Chinese fireworks and boasts a millennia-old fireworks culture.
01-03
Details -
CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)
SHANGHAI,Dec. 30,2024-- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors
01-03
Details